GENFIT

Capital/Financing Update • Aug 2, 2013

www.genfit.com

GENFIT: CONVERSIONS INTO SHARES OF 30 BONDS OCA2012-2

Lille (France), Boston (Massachusetts, United States), August 2nd, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the conversions into shares of 30 bonds OCA2012-2 in keeping with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd.

In keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting held on December 18th, 2012 and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), the Bondholder requested one first conversion on July 31th, and then two other conversions on August 1st, 2013 and on August 2nd for a total value of €300,000.

The first conversion on July 31th of 10 bonds OCA2012-2 into 22,055 new shares was performed at a conversion rate of €4.53, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five trading days (July 24th, 2013- July 30th, 2013) prior to the conversion request.

The second conversion on August 1st of 10 bonds OCA2012-2 into 21,746 new shares was performed at a conversion rate of €4.60, issue premium included, equivalent to 95% of the arithmetic mean of the volumeweighted average GENFIT share price for the five trading days (July 25th, 2013- July 31th, 2013) prior to the conversion requests.

The third conversion on August 2nd of 10 bonds OCA2012-2 into 21,278 new shares was performed at a conversion rate of €4.70, issue premium included, equivalent to 95% of the arithmetic mean of the volumeweighted average GENFIT share price for the five trading days (July 26th, 2013- August 1st, 2013) prior to the conversion requests.

As a result of these reserved share issues:

• The social capital of GENFIT has increased from €5,119,185.50 to €5,135,455.25;
• The number of shares representing the social capital of GENFIT has increased by 65,079, from 20,476,742 to 20,541,821 shares;
• The 7th €1 M installment of the bond loan agreement is completely repaid;
• The convertible loan signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd is closed, as the Company indicated during the shareholder's meeting of June 26, 2013 that the company will not execute the 8th tranche of this convertible loan.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia,

inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board Ph. +333 2016 4000

MILESTONES – Press Relations Bruno Arabian

Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr